Oxford BioMedica PLC License Patents To Emergent BioSolutions In Deal Worth up to $21.4 Million

August 19, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON (Dow Jones)--U.K. biotechnology company Oxford BioMedica PLC (OXB.LN) said Wednesday it licensed rights technology used for the development of vaccines to Emergent Biosolutions Inc. (EBS) for up to $21.4 million.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Europe

Emergent BioSolutions